Abstract
At the time of writing, more than 440 million confirmed coronavirus disease 2019 (COVID-19) cases and more than 5.97 million COVID-19 deaths worldwide have been reported by the World Health Organization since the start of the outbreak of the pandemic in Wuhan, China. During the COVID-19 pandemic, many variants of SARS-CoV-2 have arisen because of high mutation rates. N501Y, E484K, K417N, K417T, L452R and T478K in the receptor binding domain (RBD) region may increase the infectivity in several variants of SARS-CoV-2. In this study, we discovered that GB-1, developed from Chiehyuan herbal formula which obtained from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, can inhibit the binding between ACE2 and RBD with Wuhan type, K417N-E484K-N501Y and L452R-T478K mutation. In addition, GB-1 inhibited the binding between ACE2 and RBD with a single mutation (E484K or N501Y), except the K417N mutation. In the compositions of GB-1, glycyrrhizic acid can inhibit the binding between ACE2 and RBD with Wuhan type, except K417N-E484K-N501Y mutation. Our results suggest that GB-1 could be a potential candidate for the prophylaxis of different variants of SARS-CoV-2 infection because of its inhibition of binding between ACE2 and RBD with different mutations (L452R-T478K, K417N-E484K-N501Y, N501Y or E484K).
Keywords: (+)-Catechin (Pubchem CID: 9064); COVID-19; GB-1; Glycyrrhizic acid; Glycyrrhizic acid (Pubchem CID: 14982); SARS-CoV-2; Spike protein.
【저자키워드】 COVID-19, SARS-CoV-2, spike protein., glycyrrhizic acid, (+)-Catechin (Pubchem CID: 9064), GB-1, Glycyrrhizic acid (Pubchem CID: 14982), 【초록키워드】 coronavirus disease, Coronavirus disease 2019, ACE2, pandemic, Mutation, spike, SARS-COV-2 infection, COVID-19 pandemic, Infection, Spike protein, Receptor binding domain, Prophylaxis, glycyrrhizic acid, Protein, L452R, outbreak, RBD, N501Y, K417N, Wuhan, death, E484K, catechin, binding, Mutation rates, Health Organization, World Health Organization, T478K, single mutation, several variants, high mutation rates, writing, variants of SARS-CoV-2, K417N mutation, Wuhan, China, reported, addition, inhibit, inhibited, Tian, several variant, Temple, 【제목키워드】 ACE2, Mutation, SARS-CoV-2 spike protein, inhibitor, binding, Potential,